NCT07517653
Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma
Not Yet Recruiting · Phase 2 · Shanghai Zhongshan Hospital · registry updated 2026-04-08
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This study aims to investigate the efficacy and safety of SHR-1701 in combination with famitinib in the perioperative treatment of mucosal melanoma
Inclusion
- Age ≥ 18 years and ≤ 75 years, regardless of sex.
- Histopathologically confirmed mucosal melanoma.
- Focal, lymph node metastatic, or oligometastatic mucosal melanoma assessed as completely resectable by multidisciplinary team (surgery/ENT/gynecology/colorectal, radiotherapy, oncology, imaging/pathology, etc.).
- ECOG Performance Status of 0 or 1.
- Life expectancy ≥ 12 weeks.
Exclusion
- Prior treatment with PD-1/PD-L1 antibodies or anti-angiogenic agents.
- Ocular melanoma or melanoma of unknown primary site.
- History of immunodeficiency, acquired or congenital immune deficiency diseases, or organ transplantation.
- Pregnant or breastfeeding women.
- Abnormal coagulation function (APTT \> 43 seconds or INR \> 1.5 × ULN), or history of bleeding tendency or bleeding events (e.g., gastrointestinal bleeding, gastric ulcer bleeding) within 3 months before enrollment.